View Item 

Show simple item record

Cannabis education in United States Pharmacy Colleges and Schools
dc.contributor.authorKruger, Daniel J.
dc.contributor.authorKruger, Jessica S.
dc.contributor.authorBednarczyk, Edward M.
dc.contributor.authorPrescott, William Allan
dc.date.accessioned2021-06-02T21:06:19Z
dc.date.available2022-06-02 17:06:18en
dc.date.available2021-06-02T21:06:19Z
dc.date.issued2021-05
dc.identifier.citationKruger, Daniel J.; Kruger, Jessica S.; Bednarczyk, Edward M.; Prescott, William Allan (2021). "Cannabis education in United States Pharmacy Colleges and Schools." Journal of the American College of Clinical Pharmacy 4(5): 616-621.
dc.identifier.issn2574-9870
dc.identifier.issn2574-9870
dc.identifier.urihttps://hdl.handle.net/2027.42/167784
dc.description.abstractIntroductionGiven the rapid change in legal status and rise in cannabis use within the United States (U.S.), pharmacists will increasingly require competence in issues related to cannabis, especially for medical use. Pharmacy students and professionals in other health fields report low levels of cannabis knowledge, and medical cannabis users report that their knowledge is mostly from their own experiences and the internet. Several pharmacy organizations have advocated for pharmacists’ education on therapeutic and legal issues related to medical cannabis.ObjectivesTo determine the extent to which cannabis and its medical use are covered in the educational curricula of U.S. schools and colleges of pharmacy, plans for future coverage of medical cannabis, and differences by the state‐level legal status of cannabis.MethodsPharmacy schools and colleges located within the U.S. were identified via the Accreditation Council for Pharmacy Education website. A 19‐item survey was developed by researchers with experience in curriculum development and pharmaceutical issues related to cannabis. One individual from each school provided detailed information on the inclusion of medical cannabis/marijuana topics in their Doctor of Pharmacy program.ResultsTwo‐thirds (67%) of programs responded to the survey. Most programs (85.4%) had content on medical cannabis available in their curriculum, 53.1% in their required curriculum, 65.6% in their elective curriculum, and 33.0% in both their required and elective curricula. A small proportion (16.7%) had a stand‐alone medical cannabis elective course. Stand‐alone electives had the most comprehensive coverage of cannabis topics. General required and elective courses had minor differences in comprehensiveness.ConclusionResults demonstrate a moderately rapid expansion in cannabis coverage in pharmacy curricula, although coverage of cannabis topics is rarely comprehensive. Additional efforts are needed to integrate cannabis into coursework and experiential learning experiences.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.othercurriculum
dc.subject.othermarijuana
dc.subject.otherpharmacy education
dc.subject.othercannabis
dc.titleCannabis education in United States Pharmacy Colleges and Schools
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167784/1/jac51400_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/167784/2/jac51400.pdf
dc.identifier.doi10.1002/jac5.1400
dc.identifier.sourceJournal of the American College of Clinical Pharmacy
dc.identifier.citedreferenceAmerican Society of Health‐System Pharmacists. Medical Marijuana (1101). ASHP Policy Positions 1982–2019 [cited 2019 Sep 26]. Available from: https://www.ashp.org/-/media/assets/policy-guidelines/docs/browse-by-document-type-policy-positions-1982-2017-with-rationales-pdf.ashx.
dc.identifier.citedreferenceNational Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press, 2017.
dc.identifier.citedreferenceReiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J. 2009; 6: 35.
dc.identifier.citedreferenceReinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011; 43 ( 2 ): 128 – 135.
dc.identifier.citedreferenceLamonica LK, Boeri M, Anderson T. Gaps in medical marijuana policy implementation: Real‐time perspectives from marijuana dispensary entrepreneurs, health care professionals and medical marijuana patients. Drugs (Abingdon Engl). 2016; 23: 422 – 434.
dc.identifier.citedreferenceKruger DJ, Kruger JS, Collins RL. Frequent cannabis users demonstrate low knowledge of cannabinoid content and dosages. Drugs (Abingdon Engl). 2020. https://www.tandfonline.com/doi/abs/10.1080/09687637.2020.1752150.
dc.identifier.citedreferenceKruger DJ, Kruger JS, Collins RL. Cannabis enthusiasts’ knowledge of medical treatment effectiveness and increased risks from cannabis use. Am J Health Promot. 2020; 34 ( 4 ): 436 – 439.
dc.identifier.citedreferenceColizzi M, Bhattacharyya S. Does cannabis composition matter? Differential effects of delta‐9‐tetrahydrocannabinol and cannabidiol on human cognition. Curr Addict Rep. 2017; 4 ( 2 ): 62 – 74.
dc.identifier.citedreferenceCrippa JA, Zuardi AW, Martín‐Santos R, et al. Cannabis and anxiety: A critical review of the evidence. Hum Psychopharmacol. 2009; 24 ( 7 ): 515 – 523.
dc.identifier.citedreferenceCascini F, Aiello C, Di Tanna G. Increasing delta‐9‐tetrahydrocannabinol (Δ‐9‐THC) content in herbal cannabis over time: systematic review and meta‐analysis. Curr Drug Abuse Rev. 2012; 5 ( 1 ): 32 – 40.
dc.identifier.citedreferenceChandra S, Radwan MM, Majumdar CG, Church JC, Freeman TP, ElSohly MA. New trends in cannabis potency in USA and Europe during the last decade (2008‐2017). Eur Arch Psychiatry Clin Neurosci. 2019; 269 ( 1 ): 5 – 15.
dc.identifier.citedreferenceHuestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007; 4 ( 8 ): 1770 – 1804.
dc.identifier.citedreferenceMillar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018; 9: 1365.
dc.identifier.citedreferenceNational Community Pharmacists Association. State medical marijuana legislation and the pharmacist’s role. 2017.
dc.identifier.citedreferenceAmerican Pharmacists Association. Role of the pharmacist in the care of patients using cannabis. 2014–2015 APhA Policy Committee Report [cited 2019 Sep 16]. Available from: https://www.pharmacist.com/sites/default/files/files/Role%20of%20the%20Pharmacist%20in%20the%20Care%20of%20Patients%20Using%20Cannabis%20.pdf.
dc.identifier.citedreferenceAccreditation Council for Pharmacy Education. Accreditation standards and key elements for the professional program in pharmacy leading to the Doctor of Pharmacy degree “Standards 2016” [cited 2019 Sep 26]. Available from: https://www.acpe-accredit.org/pdf/Standards2016FINAL.pdf.
dc.identifier.citedreferenceBerlekamp D, Rao PSS, Patton T, Berner J. Surveys of pharmacy students and pharmacy educators regarding medical marijuana. Curr Pharm Teach Learn. 2019; 11 ( 7 ): 669 – 677.
dc.identifier.citedreferenceSmithburger PL, Zemaitis MA, Meyer SM. Evaluation of medical marijuana topics in the PharmD curriculum: A national survey of schools and colleges of pharmacy. Curr Pharm Teach Learn. 2019; 11 ( 1 ): 1 – 9.
dc.identifier.citedreferenceCaligiuri FJ, Ulrich EE, Welter KJ. Pharmacy student knowledge, confidence and attitudes toward medical cannabis and curricular coverage. Am J Pharm Educ. 2018; 82 ( 5 ): 424 – 432.
dc.identifier.citedreferenceLee J, Thomas SA, Cates DW, McGraw‐Senat CM. Improved learning experience with modified case studies courses in a pharmacy curriculum. Curr Pharm Teach Learn. 2020; 12 ( 10 ): 1224 – 1238.
dc.identifier.citedreferenceGrayson L, Vines B, Nichol K, Szaflarski JP, UAB CBD Program. An interaction between warfarin and cannabidiol, a case report. Epilepsy Behav Case Rep. 2017; 9: 10 – 11.
dc.identifier.citedreferenceHsu A, Painter NA. Probable interaction between Warfarin and inhaled and oral administration of cannabis. J Pharm Pract. 2020; 33: 915 – 918.
dc.identifier.citedreferenceWhitman A, Ostroff M, Crocetta N, Roth O, Ostroff JL. Integration of cannabidiol oil education into a pharmacy therapeutics curriculum. Curr Pharm Teach Learn. 2020; 12 ( 12 ): 1424 – 1430.
dc.identifier.citedreferenceBonn‐Miller MO, Boden MT, Bucossi MM, Babson KA. Self‐reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014; 40 ( 1 ): 23 – 30.
dc.identifier.citedreferenceKruger DJ, Kruger JS. Medical cannabis users’ comparisons between medical cannabis and mainstream medicine. J Psychoactive Drugs. 2019; 51 ( 1 ): 31 – 36.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jac51400_am.pdf
Size:
231.1KB
Format:
PDF
View/Open
Name:
jac51400.pdf
Size:
429.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.